AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
LivaNova Receives Hold Rating from Barclays, with a $58.00 Price Target.
ByAinvest
Thursday, Aug 21, 2025 5:55 am ET1min read
LivaNova (LIVN) received a Hold rating from Barclays, with a price target of $58.00. Analyst Matt Miksic from Barclays has a 4-star rating and an average return of 5.6%. LivaNova also received a Hold from TR | OpenAI – 4o’s Lila Implantra, but a Buy rating from Goldman Sachs. The company's market cap is $2.92B with a P/E ratio of -13.72.
LivaNova (LIVN), a medical technology company specializing in neuromodulation, has recently faced a mixed bag of analyst ratings and a significant restructuring move. Analysts from Barclays and TR | OpenAI – 4o’s Lila Implantra have both given a Hold rating to the company, with a price target of $58.00 from Barclays. However, Goldman Sachs has a more optimistic view, giving LivaNova a Buy rating [1].Barclays analyst Matt Miksic, who has a 4-star rating and an average return of 5.6%, cited concerns over the company's financial health and market conditions. Meanwhile, TR | OpenAI – 4o’s Lila Implantra echoed similar sentiments, while Goldman Sachs highlighted the company's potential for growth and innovation in the neuromodulation space.
LivaNova's market capitalization stands at $2.92 billion, with a P/E ratio of -13.72, indicating a highly undervalued stock. The company has been undergoing a significant restructuring aimed at improving its operational efficiency and extending its cash runway. This strategic move includes workforce reductions and cost-saving measures, similar to Fate Therapeutics' recent restructuring [2].
The company's lead product, the LivaNova Implant, continues to show promise, with ongoing clinical trials and regulatory approvals. However, the market conditions and competitive landscape in neuromodulation remain challenging.
As of the current date, July 2, 2025, LivaNova's stock price has been volatile, reflecting the diverging analyst views and the company's ongoing restructuring. Investors should closely monitor the company's financial performance and clinical trial results to gauge the potential impact on its stock price and market valuation.
References:
[1] https://www.panabee.com/news/livanova-receives-divergent-analyst-ratings-amid-restructuring
[2] https://www.ainvest.com/news/barclays-maintains-buy-rating-fate-therapeutics-2-00-price-target-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet